Comparative Pharmacology
Head-to-head clinical analysis: BRONITIN MIST versus THEOPHYL 225.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRONITIN MIST versus THEOPHYL 225.
BRONITIN MIST vs THEOPHYL-225
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BRONITIN MIST contains isoproterenol, a non-selective beta-adrenergic agonist that stimulates beta-1 and beta-2 receptors, leading to bronchodilation via relaxation of bronchial smooth muscle, increased heart rate, and increased contractility.
Theophylline is a methylxanthine that inhibits phosphodiesterase, leading to increased intracellular cAMP levels, and antagonizes adenosine receptors (A1, A2). This results in bronchodilation, reduced airway inflammation, and enhanced diaphragmatic contractility.
For acute bronchospasm: 1-2 inhalations (0.1 mg per inhalation) via aerosol inhaler every 4-6 hours as needed.
225 mg orally every 6 hours; adjust based on serum theophylline levels to maintain therapeutic range 10-20 mcg/mL.
None Documented
None Documented
Terminal elimination half-life is 3-4 hours in adults; may be prolonged in hepatic or renal impairment, requiring dose adjustment.
Terminal half-life: 3–12 hours (adults); shorter (1–5 hours) in children and smokers; prolonged in hepatic cirrhosis, heart failure, or elderly. Steady-state achieved in 1–2 days.
Primarily renal (approximately 70-80% as unchanged drug and metabolites); biliary/fecal excretion accounts for 20-30%.
Renal: 10% unchanged; hepatic metabolism (CYP1A2, CYP3A4) accounts for ~90% of elimination, with metabolites (e.g., 3-methylxanthine, 1,3-dimethyluric acid) excreted renally.
Category C
Category C
Bronchodilator
Bronchodilator